Linda E. Carlson, PhD

home / authors / linda-e-carlson-phd

Articles

Updated SIO/ASCO Guidelines Recommend Integrative Therapies to Reduce Anxiety/Depression in Patients With Cancer

Updated SIO/ASCO Guidelines Recommend Integrative Therapies to Reduce Anxiety/Depression in Patients With Cancer

Linda E. Carlson, PhD
March 7th 2024

Linda E. Carlson, PhD, RPsych, discusses the recent updates from SIO/ASCO to the anxiety and depression guidelines for patients with cancer.

SIO/ASCO Guidelines for Integrative Therapies to Manage Anxiety/Depression

SIO/ASCO Guidelines for Integrative Therapies to Manage Anxiety/Depression

Linda E. Carlson, PhD
January 29th 2024

Therapies like yoga, music therapy, acupuncture, and natural health remedies have proven to be beneficial in mitigating anxiety and depression in adults with cancer, according to Linda E. Carlson, PhD, RPsych.

Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

Danielle Gentile, PhD;Dori Beeler, PhD;Xin Shelley Wang, MD, MPH;Eran Ben-Ayre, MD;Suzanna Maria Zick, ND, MPH;Ting Bao, MD, DABMA, MS;Linda E. Carlson, PhD;Ricardo Ghelman, MD, PhD;Viraj A. Master, MD, PhD;Debu Tripathy, MD;W. Iris Zhi, MD, PhD
May 16th 2022

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Expanding Immunotherapy Use in Early-Stage Breast Cancer
Published: July 14th 2025 | Updated: July 25th 2025
Expanding Immunotherapy Use in Early-Stage Breast Cancer